1. Home
  2. SLNH vs BDTX Comparison

SLNH vs BDTX Comparison

Compare SLNH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

N/A

Current Price

$0.55

Market Cap

126.7M

Sector

Technology

ML Signal

N/A

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.89

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLNH
BDTX
Founded
1961
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.7M
104.0M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
SLNH
BDTX
Price
$0.55
$1.89
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$2.75
★ $10.00
AVG Volume (30 Days)
★ 11.7M
845.5K
Earning Date
11-20-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
80.41
★ 130.71
EPS
N/A
★ N/A
Revenue
★ $38,021,000.00
N/A
Revenue This Year
$106.45
N/A
Revenue Next Year
$6.11
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 80.49
N/A
52 Week Low
$0.45
$1.60
52 Week High
$2.55
$4.94

Technical Indicators

Market Signals
Indicator
SLNH
BDTX
Relative Strength Index (RSI) 37.15 52.35
Support Level N/A $1.65
Resistance Level $0.73 $1.93
Average True Range (ATR) 0.07 0.15
MACD 0.01 0.00
Stochastic Oscillator 36.37 50.00

Price Performance

Historical Comparison
SLNH
BDTX

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: